Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Jonathan D. Adachi(St. Peter's Hospital), Simon Pack(Procter & Gamble (United States)), David L. Kendler(University of British Columbia), W. C. Sturtridge, Brian C. Lentle(University of British Columbia), Janet Pope(St Joseph's Health Care), Robert G. Josse(Western University), Jacques P. Brown(Centre hospitalier de l'Université Laval), John G. Hanly(Queen Elizabeth II Health Sciences Centre), Arkadi Chines(Procter & Gamble (United States)), Alan Tenenhouse(St. Vincent's Birmingham), Tassos Anastassiades, A. Jovaisas, Zebulun D. Horowitz, Reginald Dias, David A. Hanley(University of Calgary), Louis-George Ste.-Marie(Hôpital Saint-Luc), Wojciech P. Olszynski(University of Saskatchewan), W. Bensen(St. Joseph Hospital), Anthony B. Hodsman(Western University)
Cited by 694
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Body mass index as a predictor of fracture risk: A meta-analysis
|Osteoporosis International|2005|1.6k
Predictive Value of BMD for Hip and Other Fractures
|Journal of Bone and Mineral Research|2005|1.5k